Debiopharm Group, a global biopharmaceutical company, and Pharmaleads, a drug discovery and early development company, have signed an exclusive license agreement for the development, registration and commercialization of a small molecule called Debio 0827 or PL37, about to enter Phase I clinical trials.

[News Source]